Cart
sales@molnova.com
2,6-Dichlorodiphenylamine
CAS No. 15307-93-4
2,6-Dichlorodiphenylamine ( 2,6-Dichloro-N-phenylaniline )
Catalog No. M28167 CAS No. 15307-93-4
2,6-Dichlorodiphenylamine shows activity against Candida albicans infections. 2,6-Dichlorodiphenylamine elevated the MIC by 4-fold of diclofenac sodium (DFNa).
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 500MG | 37 | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product Name2,6-Dichlorodiphenylamine
-
NoteResearch use only, not for human use.
-
Brief Description2,6-Dichlorodiphenylamine shows activity against Candida albicans infections. 2,6-Dichlorodiphenylamine elevated the MIC by 4-fold of diclofenac sodium (DFNa).
-
Description2,6-Dichlorodiphenylamine shows activity against Candida albicans infections. 2,6-Dichlorodiphenylamine elevated the MIC by 4-fold of diclofenac sodium (DFNa).
-
Synonyms2,6-Dichloro-N-phenylaniline
-
PathwayGPCR/G Protein
-
TargetAntibacterial
-
RecptorGPR109B
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number15307-93-4
-
Formula Weight238.1
-
Molecular FormulaC12H9Cl2N
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESClc1cccc(Cl)c1Nc1ccccc1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Skinner PJ, et al. 3-Nitro-4-amino benzoic acids and 6-amino nicotinic acids are highly selective agonists of GPR109b. Bioorg Med Chem Lett. 2007 Dec 1;17(23):6619-22.
molnova catalog
related products
-
Morinidazole
Morinidazole shows antibacterial activity and can be used in studies about bacterial infections research such as appendicitis and pelvic inflammatory disease caused by anaerobic bacteria.
-
Fosfomycin calcium
Fosfomycin calcium is an antibiotics, used in urinary tract infections and intestinal infections caused by susceptible strains.
-
GSK693
GSK693 (GSK-693) is a potent, direct inhibitor of M. tuberculosis enoyl-ACP reductase (InhA) with IC50 of 7 nM.
